Teva Pharmaceuticals’ (NYSE: TEVA) first quarter 2020 results beat consensus estimates. The drugmaker reported adjusted earnings of $0.76 per share on revenue of $4.4 billion. Wall Street expected Teva to earn $0.59 per share on revenue of $4.15 billion. TEVA stock surged about 7% in the pre-market trading session.
GAAP net income attributable to ordinary shareholders was $69 million or $0.06 per share in the first quarter of 2020, compared to GAAP net loss of $105 million or $0.10 per share in the first quarter of 2019.
The Tel Aviv, Israel-based company confirmed its outlook for fiscal 2020. EPS is expected to be between $2.30 and $2.55, while revenue is targeted to be in the range of $16.6 billion to $17 billion for fiscal 2020.
The massive slowdown in the IPO market continued in the second half as the challenges posed by high inflation and interest rate hikes weighed on investor confidence. Meanwhile, there is
The automotive sector is one of the worst affected by the combination of high inflation and rising interest rates. Consumers have become more cautious and are prioritizing their purchases with
The IPO market has witnessed muted activity this year, and things don’t seem to have improved in the second half. The upcoming public listing of video game technology firm Ultimax